Safety and feasibility of countering neurological impairment by intravenous administration of autologous cord blood in cerebral palsy

Journal of Translational Medicine

Yoon-Sun Yang⁵  Wonil Oh⁵  Soo-Jin Choi⁵  Su Min Son⁷  Jong-Hwa Lee⁶  Hee-Jin Kim²  Young-Jun Lee¹  Yun Young Choi⁸  Mi Jung Kim³  Jang Soo Um³  Hyung Sun Kim³  Se-In Oh³  Hye-Ryeong Kang⁴  Hyun-Joo Jun⁴  Jin Hwa Moon⁴  Kyung Vin Choi⁴  Young-Ho Lee² 

[1] Department of Radiology, Hanyang University Medical Center, Seoul, Korea;Cell Therapy Center for Intractable Neurological Disorders, Hanyang University Medical Center, Seoul, Korea;Department of Rehabilitation Medicine, Hanyang University Medical Center, Seoul, Korea;Department of Pediatrics & Cord Blood Clinic, Hanyang University Medical Center, Seoul, Korea;Medipost Biomedical Research Institute, Seoul, Korea;Department of Pediatrics, Wonkwang University Medical Center, Sanbon, Korea;Department of Physical Medicine & Rehabilitation, Yeungnam University Medical Center, Daegu, Korea;Department of Nuclear Medicine, Hanyang University Medical Center, Seoul, Korea

关键词: Cell therapy;    Mononuclear cells;    Cord blood;    Cerebral palsy;   

Others  :  1206023
DOI  :  10.1186/1479-5876-10-58

 received in 2012-01-18, accepted in 2012-03-23,  发布年份 2012

【 摘 要 】

Backgrounds

We conducted a pilot study of the infusion of intravenous autologous cord blood (CB) in children with cerebral palsy (CP) to assess the safety and feasibility of the procedure as well as its potential efficacy in countering neurological impairment.

Methods

Patients diagnosed with CP were enrolled in this study if their parents had elected to bank their CB at birth. Cryopreserved CB units were thawed and infused intravenously over 10~20 minutes. We assessed potential efficacy over 6 months by brain magnetic resonance imaging (MRI)-diffusion tensor imaging (DTI), brain perfusion single-photon emission computed tomography (SPECT), and various evaluation tools for motor and cognitive functions.

Results

Twenty patients received autologous CB infusion and were evaluated. The types of CP were as follows: 11 quadriplegics, 6 hemiplegics, and 3 diplegics. Infusion was generally well-tolerated, although 5 patients experienced temporary nausea, hemoglobinuria, or urticaria during intravenous infusion. Diverse neurological domains improved in 5 patients (25%) as assessed with developmental evaluation tools as well as by fractional anisotropy values in brain MRI-DTI. The neurologic improvement occurred significantly in patients with diplegia or hemiplegia rather than quadriplegia.

Conclusions

Autologous CB infusion is safe and feasible, and has yielded potential benefits in children with CP.

【 授权许可】

   
2012 Lee et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Gluckman E, Broxmeyer HA, Auerbach AD, Friedman HS, Douglas GW, Devergie A, Esperou H, Thierry D, Socie G, Lehn P: Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med 1989, 321:1174-1178.
• [2]Kurtzberg J: Update on umbilical cord blood transplantation. Curr Opin Pediatr 2009, 21:22-29.
• [3]Staba SL, Escolar ML, Poe M, Kim Y, Martin PL, Szabolcs P, Allison-Thacker J, Wood S, Wenger DA, Rubinstein P, Hopwood JJ, Krivit W, Kurtzberg J: Cord-blood transplants from unrelated donors in patients with Hurler's syndrome. N Engl J Med 2004, 350:1960-1969.
• [4]Escolar ML, Poe MD, Provenzale JM, Richards KC, Allison J, Wood S, Wenger DA, Pietryga D, Wall D, Champagne M, Morse R, Krivit W, Kurtzberg J: Transplantation of umbilical-cord blood in babies with infantile Krabbe's disease. N Engl J Med 2005, 352(20):2069-2081.
• [5]Matsumoto T, Mugishima H: Non-hematopoietic stem cells in umbilical cord blood. Int J Stem Cell 2009, 2:83-89.
• [6]Fan CG, Zhang QJ, Tang FW, Han ZB, Wang GS, Han ZC: Human umbilical cord blood cells express neurotrophic factors. Neurosci let 2005, 380:322-325.
• [7]Newman MB, Willing AE, Manresa JJ, Sanberg CD, Sanberg PR: Cytokines produced by cultured human umbilical cord blood cells: Implications for brain repair. Exp Neurol 2006, 199:201-208.
• [8]Joyce N, Annett G, Wirthlin L, Olson S, Bauer G, Nolta JA: Mesenchymal stem cells for the treatment of neurodegenerative disease. Regen Med 2010, 5:933-946.
• [9]Chen J, Sanberg PR, Li Y, Wang L, Lu M, Willing AE, Sanchez-Ramos J, Chopp M: Intravenous administration of human umbilical cord blood reduces behavioral deficits after stroke in rats. Stroke 2001, 32:2682-2688.
• [10]Papadopoulos KI, Low SSS, Aw TC, Chantarojanasiri T: Safety and feasibility of autologous umbilical cord blood transfusion in 2 toddlers with cerebral palsy and the role of low dose granulocyte-colony stimulating factor injections. Restor Neurol Neurosci 2011, 29:17-22.
• [11]Prabhakar S, Muthaian R, Chabbra R, Anand A: Analysis of homing potential of marrow-derived mononuclear cells in an experimentally-induced brain stroke mouse model. Brain Inj 2010, 24:1485-1490.
• [12]Trivedi R, Gupta RK, Shah V, Tripathi M, Rathore RK, Kumar M, Pandey CM, Narayana PA: Treatment-induced plasticity in cerebral palsy: a diffusion tensor imaging study. Pediatr Neurol 2008, 39:341-349.
• [13]Trivedi R, Agarwal S, Shah V, Goyel P, Paliwal VK, Rathore RK, Gupta RK: Correlation of quantitative sensorimotor tractography with clinical grade of cerebral palsy. Neuroradiology 2010, 52:759-765.
• [14]Yoshida S, Hayakawa K, Yamamoto A, Okano S, Kanda T, Yamori Y, Yoshida N, Hirota H: Quantitative diffusion tensor tractography of the motor and sensory tract in children with cerebral palsy. Dev Med Child Neurol 2010, 52:935-940.
• [15]Hoon AH Jr, Stashinko EE, Nagae LM, Lin DD, Keller J, Bastian A, Campbell ML, Levey E, Mori S, Johnston MV: Sensory and motor deficits in children with cerebral palsy born preterm correlate with diffusion tensor imaging abnormalities in thalamocortical pathways. Dev Med Child Neurol 2009, 51:697-704.
• [16]Lu D, Chen B, Liang Z, Deng W, Jiang Y, Li S, Xu J, Wu Q, Zhang Z, Xie B, Chen S: Comparison of bone marrow mesenchymal stem cells with bone marrow-derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double-blind, randomized, controlled trial. Diabetes Res Clin Pract 2011, 92:26-36.
• [17]Giraldi-Guimarães A, Rezende-Lima M, Bruno FP, Mendez-Otero R: Treatment with bone marrow mononuclear cells induces functional recovery and decreases neurodegeneration after sensorimotor cortical ischemia in rats. Brain Res 2009, 1266:108-120.
• [18]Reich DM, Hau S, Stahl T, Scholz M, Naumann W, Emmrich F, Boltze J, Kamprad M: Neuronal hypoxia in vitro: investigation of therapeutic principles of HUCB-MNC and CD133+ stem cells. BMC Neurosci 2008, 9:91. BioMed Central Full Text
• [19]Vendrame M, Cassady CJ, Newcomb J, Bulter T, Pennypacker KR, Zigova T, Sanberg CD, Sanberg PR, Willing AE: Infusion of human umbilical cord blood cells in rat model of stroke dose-dependently rescues behavioral deficits and reduces infarct volume. Stroke 2004, 35(10):2390-2395.
• [20]Willing AE, Lixian J, Milliken M, Poulos S, Zigova T, Song S, Hart C, Sanchez-Ramos J, Sanberg PR: Intravenous versus intrastriatal cord blood administration in a rodent model of stroke. J Neurosci Res 2003, 73:296-307.
• [21]Sun J, Allison J, McLaughlin C, Sledge L, Waters-Pick B, Wease S, Kurtzberg J: Differences in quality between privately and publicly banked umbilical cord blood units: a pilot study of autologous cord blood infusion in children with acquired neurologic disorders. Transfusion 2010, 50:1980-1987.
• [22]Bachstetter AD, Pabon MM, Cole MJ, Hudson CE, Sanberg PR, Willing AE, Bickford PC, Gemma C: Peripheral injection of human umbilical cord blood stimulates neurogenesis in the aged rat brain. BMC Neurosci 2008, 14:9-22.
• [23]Xiao J, Nan Z, Motooka Y, Low WC: Transplantation of a novel cell line population of umbilical cord blood stem cells ameliorates neurological deficits associated with ischemic brain injury. Stem Cells Dev 2005, 14:722-733.
• [24]Stolp HB, Dziegielewska KM: Review: Role of developmental inflammation and blood-brain barrier dysfunction in neurodevelomental and neurodegenerative diseases. Neuropathol Appl Neurobiol 2009, 35:132-146.
• [25]Aloisi F: Immune function of microglia. Glia 2001, 36:165-179.
• [26]Flugel A, Bradl M, Kreutzberg GW, Graeber MB: Transformation of donor-derived bone marrow precursors into host microglia during autoimmune CNS inflammation and during the retrograde response to axotomy. J Neurosci Res 2001, 66:74-82.
• [27]Ekdahl CT, Kokaia Z, Lindvall AO: Review: Brain inflammation and adult neurogenesis: The dual role of microglia. Neuroscience 2009, 158:1021-1029.
• [28]Morgan SC, Taylor DL, Pocock JM: Microglia release activators of neuronal proliferation mediated by activation of mitogen-activated protein kinase, phosphatidylinositol-3-kinase/Akt and delta-Notch signalling cascades. J Neurochem 2004, 90:89-101.